Proactive Investors - Run By Investors For Investors

MaxCyte updates on plans to simplify share structure

MaxCyte currently has two classes of shares: unrestricted and Regulation S restricted
share certificate
The move is intended to help both trading liquidity and transparency for shareholders

MaxCyte (LON:MXCT) said from November 28 all common stock will be held as unrestricted shares as it provided an update on plans to merge two separate classes of equity.

The move is intended to help both trading liquidity and transparency for shareholders.

MaxCyte currently has two classes of shares: unrestricted and Regulation S restricted. For more information click here.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Related Articles

cancer
February 26 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
A doctor's stethoscope and a marijuana plant
February 23 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use